Needham & Company LLC Reaffirms “Buy” Rating for Artiva Biotherapeutics (NASDAQ:ARTV)

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “buy” rating reiterated by equities researchers at Needham & Company LLC in a report issued on Wednesday,Benzinga reports. They presently have a $18.00 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 196.05% from the company’s previous close.

Several other brokerages also recently issued reports on ARTV. HC Wainwright raised their price target on Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Jefferies Financial Group upgraded shares of Artiva Biotherapeutics to a “strong-buy” rating in a research note on Tuesday, November 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

Artiva Biotherapeutics Stock Up 6.5%

Shares of NASDAQ ARTV opened at $6.08 on Wednesday. The business’s 50 day moving average price is $4.63 and its two-hundred day moving average price is $3.90. The company has a market cap of $149.26 million, a PE ratio of -2.36 and a beta of 2.16. Artiva Biotherapeutics has a twelve month low of $1.47 and a twelve month high of $7.36.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Tuesday, March 10th. The company reported ($0.84) EPS for the quarter. As a group, research analysts anticipate that Artiva Biotherapeutics will post -4.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Prelude Capital Management LLC bought a new stake in Artiva Biotherapeutics during the third quarter worth about $41,000. Bank of America Corp DE increased its holdings in Artiva Biotherapeutics by 225.8% in the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after buying an additional 11,190 shares during the period. Bridgeway Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics in the 2nd quarter valued at approximately $53,000. Qube Research & Technologies Ltd bought a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $58,000. Finally, Jane Street Group LLC bought a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $67,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.